Sickle Cell Disease: Global Disparities in Prevalance and Outcomes

Sickle Cell Disease: Global Disparities in Prevalance and Outcomes 150 150 Abbie Roth

Unique challenges exist for people with sickle cell disease depending on where they live.

An estimated 300,000 to 500,000 babies worldwide are born with sickle cell disease (SCD) each year. In Africa and India, where SCD is most prevalent, newborn testing is not performed, and many children with sickle cell disease die before they are even diagnosed.

“Their death certificates will say malaria, anemia or pneumonia, though the real cause is sickle cell disease,” says Patrick McGann, MD, assistant professor in the Department of Pediatrics at University of Cincinnati.

Even in developed countries such as the United States, where the incidence of SCD is approximately 3,000 children each year, SCD is not easily treated. Children benefit from newborn screening and early initiation of treatment, but SCD is still characterized by extremely painful sickle cell crises and deadly comorbidities such as infections, lung disease and asthma.

Only one drug — hydroxyurea — is FDA approved to treat SCD. It works by decreasing the frequency of sickle cell crises. In Africa, it costs about $2/day, if it is available at all. The average family income in many parts of Africa is less than $2/day, leaving treatment out of reach.

“Sickle cell disease is a very painful condition with limited treatment options,” says Anthony Villella, MD, director of the Comprehensive Sickle Cell and Thalassemia Program at Nationwide Children’s Hospital. “Historically, there has been a serious lack of awareness and research funding for the development of novel therapies for sickle cell disease. Now, pharmaceutical companies are starting to commit resources to sickle cell research. I am optimistic that we will have more options in the future.”

References:

  1. McGann PT. Strategies to Address the Global Burden of Sickle Cell Anemia. Translational Research in Heme/Onc/BMT Lecture at Nationwide Children’s Hospital. 2015 May 22.
  2. Sickle Cell Disease Association of America. www.sicklecelldisease.org
  3. American Society of Hematology. www.hematology.org

About the author

Abbie Roth, MWC, is a passionate communicator of science. As the managing editor for science communication at Nationwide Children’s Hospital, she shares stories about innovative research and discovery with audiences ranging from parents to preeminent researchers and leaders. Before coming to Nationwide Children’s, Abbie used her communication skills to engage audiences with a wide variety of science topics. As a subject-matter expert, she developed content for science education materials for McGraw-Hill Education, bringing science concepts to life for middle and high school aged students. She also provided technical editing for manuscripts spanning the American Chemical Society journal portfolio, in addition to serving as production lead for ACS Synthetic Biology. Abbie earned her BS in Life Sciences at Otterbein University while working at the Tan & Cardinal newspaper and minoring in Public Relations. She is a Medical Writer Certified®, credentialed by the American Medical Writers Association.